Business Context and Reporting Period
Coherus BioSciences, Inc. (CHRS) filed a Current Report on Form 8-K on September 14, 2022. The filing details the execution of a specific tranche under a senior secured term loan facility previously established in January 2022.
Key Financial Metrics and Debt Structure
- Debt Drawdown: The Company drew down an additional $50.0 million principal amount (Tranche D Loan) on September 14, 2022.
- Total Facility Size: The Loan Agreement provides for a senior secured term loan facility of up to $300.0 million, funded in four tranches.
- Interest Rate: Term Loans bear interest at 8.25% plus three-month LIBOR per annum, with a LIBOR floor of 1.00%.
- Maturity Date: The loans mature on the fifth anniversary of the Tranche A Closing Date (January 5, 2027) or October 15, 2025, contingent on the outstanding balance of the Company's 1.5% Convertible Senior Subordinated Notes due 2026.
- Repayment Terms: Principal repayment consists of five equal quarterly payments commencing after the 48-month anniversary of the Tranche A Closing Date.
- Additional Capacity: The Company retains the right to request an uncommitted additional facility of up to $100.0 million subject to new terms.
Material Changes and Triggers
The drawdown of the $50.0 million Tranche D Loan was triggered by the first U.S. Food and Drug Administration (FDA) approval of a Biologics License Application (BLA) for the Company's product candidate CHS-201 (ranibizumab biosimilar). This follows the funding of Tranche A ($100.0 million) in January 2022 and Tranche B ($100.0 million) in March 2022. Tranche C ($50.0 million) remains available at the Company's option pending FDA approval of CHS-007 (toripalimab).
Outlook, Risks, and Contingencies
- Regulatory Contingency: Future funding of Tranche C is contingent upon the FDA approval of the BLA for CHS-007.
- Interest Rate Risk: The interest rate is tied to LIBOR; the agreement includes provisions to replace LIBOR with the Secured Overnight Financing Rate (SOFR) upon cessation of LIBOR.
- Convertible Notes Interaction: The maturity date of the term loans is accelerated to October 15, 2025, if the outstanding principal of the 1.5% Convertible Senior Subordinated Notes due 2026 exceeds $50.0 million on October 1, 2025.
Investor Verification Checklist
- Verify the total outstanding debt balance post-drawdown against the $300.0 million facility cap.
- Confirm the status of the BLA for CHS-007 (toripalimab) to assess the likelihood of funding the remaining $50.0 million Tranche C.
- Review the outstanding balance of the 1.5% Convertible Senior Subordinated Notes due 2026 to determine the applicable maturity date for the term loans.
- Assess the impact of the 8.25% + LIBOR interest rate on future cash flow requirements, particularly given the LIBOR floor.